Matthew is a General Partner and the head of OrbiMed’s Royalty and Credit Opportunities team. He has been with OrbiMed since 2010 and helped launch the firm’s first dedicated royalty and credit fund. He has led over $5 billion of investments in the structured credit and royalty space. Prior to joining OrbiMed, Matthew was responsible for pharmaceutical licensing and acquisitions at Ikaria. He has worked in healthcare for 30 years, including life sciences investing at Fortress Investment Group and global commercial strategy at GSK. Matthew received his M.B.A. from Duke University with a concentration in Health Sector Management. At OrbiMed, he is focused on providing structured capital solutions to fund growth across healthcare and life sciences.